Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction

The American Journal of Cardiology
B I Jugdutt, J W Warnica

Abstract

The question of vascular tolerance was examined in 154 patients with acute myocardial infarction (64 anterior, 90 inferior) who were treated with prolonged low dose intravenous nitroglycerin in a recent randomized placebo-controlled study. The dose of nitroglycerin was carefully titrated to decrease mean blood pressure by 10% in normotensive patients and 30% in hypertensive (blood pressure greater than 140/90 mm Hg) patients, but not less than 80 mm Hg. Tolerance was defined as the need to increase the dose to maintain this hemodynamic effect. It was labelled "true" if chest pain was absent and "apparent" if chest pain was present. Group analysis of dose, pain scores, hemodynamic, 2-dimensional echocardiographic and clinical parameters monitored serially before and after therapy indicated benefit with nitroglycerin over placebo despite equalizing of blood pressures after 10 hours. Reversal of blood pressures and volumes after discontinuing nitroglycerin suggested lack of significant tolerance. However, detailed individual analysis suggested significant hemodynamic tolerance in 37 patients (24%), both in the true tolerance (12%) and apparent tolerance (12%) subgroups. Tolerance appeared early, requiring the dose to be increased ...Continue Reading

References

Jan 1, 1975·Circulation·J T FlahertyB Pitt
Mar 1, 1986·Annals of Internal Medicine·R A JordanJ Franciosa
Sep 24, 1987·The New England Journal of Medicine·M PackerM Yushak
Jun 1, 1988·Circulation·D ZimrinH L Fung
Jun 4, 1987·The New England Journal of Medicine·J O ParkerG Moe

❮ Previous
Next ❯

Citations

Aug 1, 1994·Cardiovascular Drugs and Therapy·B I Jugdutt
May 30, 1996·The American Journal of Cardiology·B I Jugdutt
Aug 20, 1994·Lancet·M Sardina, J Mizrahi
Dec 10, 1998·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M V MonzaniM Sardina
Jan 1, 1992·Acta Anaesthesiologica Scandinavica. Supplementum·G Ohqvist
Feb 27, 2007·Vascular Health and Risk Management·Bodh I Jugdutt
Nov 18, 1991·The American Journal of Cardiology·B I Jugdutt
Sep 24, 1992·The American Journal of Cardiology·J D Horowitz
Sep 24, 1992·The American Journal of Cardiology·B I Jugdutt
Nov 27, 1992·The American Journal of Cardiology·E A Amsterdam
Dec 16, 1993·The American Journal of Cardiology·B I Jugdutt
Feb 24, 2001·Alimentary Pharmacology & Therapeutics·D Tripathi, P C Hayes
Jan 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T IwaoK Tanikawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.